🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Recruitingn/aAges any - anyAllAstraZeneca
NCT06862206 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply: * Patients must to be 12 years old (inclusive) at the time of signing the informed consent. * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician. * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent. * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion criteria -Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Patients currently participating in any other clinical trial. * Known history of allergy or reaction to any component of the study treatment formulation. * Malignancy of any kind. * Patients with prior or ongoing treatment with benralizumab.
💊

What it tests

  • benralizumab
📍

Where

36 sites
Research Site
Anhui, China
Research Site
Anning, China
Research Site
Beijing, China
Research Site
Binzhou, China
Research Site
Changzhou, China
Research Site
Fenyang, China
Research Site
Guangdong, China
Research Site
Guangzhou, China

…and 28 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy